The symposia will consist of peer-reviewed platform and poster presentations designed to communicate recent research advances in the field of Parkinson’s disease, Huntington’s disease, ataxia, dystonia, myoclonus, Tourette’s syndrome, tremor and other Movement Disorders to professionals in neurology and related disciplines. Practitioners, educators, and researchers are invited to attend. Abstracts of platform and poster presentations representing original material will be published in the September 2006 issue of Movement Disorders.

At the conclusion of this session, participants should be able to: 1) Identify by scholarly review, oral presentation and group discussion the current research into the diagnosis, prevention and treatment of Parkinson’s disease and other Movement Disorders; 2) Identify the important advances in research and clinical treatments relating to a variety of Movement Disorders; 3) Discuss new pharmacological and non-pharmacological treatment options available for Parkinson’s disease and other Movement Disorders; 4) Identify the mechanisms (genetic, environmental, pathophysiology, neurobiology) linked to Parkinson’s disease and other Movement Disorders; and 5) Discuss the diagnostic approaches and tools available for Parkinson’s disease and other Movement Disorders.

MORNING SESSION: 8:15 AM–NOON
The morning session consists of a keynote speaker and 11 presentations by the following individuals with allotted time for questions and answers after each presenter.

8:15-9:00 AM
KEYNOTE ADDRESS: New Insights into the Etiology of Parkinson’s Disease and Symptom-Linked Adaptations
D. James Surmeier, PhD. Northwestern University, Feinberg School of Medicine, Chicago, IL, USA.

9:00-9:15 AM
Gene Therapy for Parkinson’s Disease with Subthalamic Nucleus AAV-GAD: FDG PET Results
A. Feigin,1 C. Tang,1 M. During,2 M. Kaplitt,2 D. Eidelberg.1 1Feinstein Institute for Medical Research, North Shore – LIJ Health System, Manhasset, NY; 2Weill – Cornell Medical Center, New York, NY, USA.

9:15-9:30 AM
Is Pathological Gambling in Parkinson’s Disease a Compulsive or Impulsive Disorder?
M.A. Shapiro, 1 Y-L Chang, 2 M. S. Okun, 1 R.L. Rodriguez, 2 F. M. Skidmore, 1 and H. H. Fernandez.1 1Department of Neurology, University of Florida College of Medicine, Gainesville, FL; 2Department of Clinical and Health Psychology, University of Florida, Gainesville, FL, USA.

9:30-9:45 AM
Assessment of Compulsive Behaviors in Parkinson’s Disease
J.S. Hui,1 G. Murdock,1 J. Moon,2 D. Fly,2 M. Gomez,1 M. Langille,1 S. Christensen,1 M.D. Welsh.1 1University of Southern California, Los Angeles, CA; 2Fuller Theological Seminary School of Psychology, Pasadena, CA, USA.

9:45-10:00 AM
Deep Brain Stimulation for Treatment of Parkinson’s Disease: Longitudinal Perspectives of Quality of Life among Patients and Caregivers
C. McRae,1 E. Sullivan,1 G. Hartsock,1 L.M. Winfield,2 R.R. Goodman,2 G.M. McKhann,2 S.L. Pullman,2 B. Ford.2 1University of Denver, Denver, CO; 2Center for Movement Disorders Surgery, Columbia-Presbyterian Medical Center, New York, NY, USA.

10:00-10:15 AM
BREAK

10:15-10:30 AM
Assessment of Brain Iron and a Neuronal Marker in Patients with Parkinson’s Disease Using Novel MRI Contrasts
S. Michaeli, D. Sorce, G. Öz, K. Ugurbil, M. Garwood, P. Tuite. University of Minnesota, Minneapolis, MN, USA.

10:30-10:45 AM
Does Perceived Cognitive Dysfunction on the PDQ-39 Correlate with Actual Cognitive Dysfunction in Parkinson Disease?
M.S. Okun,1 A. Roy, 2 C.W. Garvan,2 D.Bowers,3 H.H. Fernandez,1 C. Jacobson,1 R.L. Rodriguez,1 D. Loring,1 K. Meador.1 1Department of Neurology, University of Florida Movement Disorders Center, McKnight Brain Institute, Gainesville, FL; 2Division of Biostatistics, University of Florida Movement Disorders Center, McKnight Brain Institute, Gainesville, FL; 3Department of Clinical and Health Psychology, University of Florida Movement Disorders Center, McKnight Brain Institute, Gainesville, FL, USA.

10:45-11:00 AM
The POETRY Study: The Safety, Tolerability and Efficacy of Estrogen Replacement Therapy in Post-Menopausal Women with Parkinson’s Disease (PD)
Parkinson Study Group1 (L.M. Shulman,2 presenting on behalf of the POETRY Steering Committee, Investigators and Coordinators). 1University of Rochester School of Medicine, Rochester, NY; 2University of Maryland School of Medicine, Baltimore, MD, USA.

11:00-11:15 AM
Ropinirole 24-Hour Prolonged Release Improves Sleep but Does Not Increase Daytime Sleepiness when Used as Adjunctive Therapy in Patients with Parkinson’s Disease Not Optimally Controlled by L-Dopa
M.A. Stacy,1 K.D. Sethi,2 N.L. Earl.3 1Duke University Medical Center, Durham, NC; 2Medical College of Georgia, Augusta, GA; 3GlaxoSmithKline, Research Triangle Park, NC, USA.

11:15-11:30 AM
LATE-BREAKING RESEARCH
ACP-103 Reduces Psychosis Without Impairing Motor Function in Parkinson's Disease
J. Friedman,1 K.E. Vanover,2 E.M. Taylor,2 D. Weiner,2 R.E. Davis,3 D.P. van Kammen.2 1Brown University, Warwick, RI; 2Acadia Pharmaceuticals, San Diego, CA; 33-D Pharmaceutical Consultants, San Diego, CA, USA.

11:30-11:45 AM
LATE-BREAKING RESEARCH
Exercise Induced Behavioral Recovery and Plasticity in the MPTP-Mouse Model of Parkinson’s Disease
G. M. Petzinger,1,3 P. Arevalo,2 M. Vuckovic,2 P. Turnquist,2 E. Hogg,2 J. Walsh2, G. Akopian2, C. Meshul4, A. Abernathy1, M. Ramirez1, B. Fisher1,3 and M.W. Jakowec.1,3 1Dept. Neurology; 2Davis School of Gerontology; 3Dept. Biokinesiology and Physical Therapy; University of Southern California, Los Angeles, CA; 4VA Medical Center, OHSU, Portland, OR, USA.

11:45-12:00 AM
LATE-BREAKING RESEARCH
Deep Brain Stimulation vs. Best Medical Therapy for Parkinson’s Disease: Patient Outcomes from the VA CSP#468 Prospective, Randomized, Multi-Center Trial
The CSP #468 Study Group (Frances M. Weaver, presenter), VA Hospital, Hines, IL, USA.

12:00-1:30 PM
LUNCH - Posters will be staffed from Noon to 1:30 PM in the Grand Ballroom E & F.

AFTERNOON SESSION: 1:30-4:30 PM
The afternoon session consists of a keynote speaker and 8 presentations by the following individuals with allotted time for questions and answers after each presenter.

1:30-2:15 PM
KEYNOTE ADDRESS: Ion Channel Dysfunction in the Dominant Spinocerebellar Ataxias
Stefan M. Pulst, MD. Cedars-Sinai Medical Center, Los Angeles, CA, USA.

2:15-2:30 PM
Predictors of Response to Tetrabenazine in Huntington’s Disease
F.J. Marshall,1 S. Eberly,2 S. Frank,2 D. Oakes,1 and the Huntington Study Group/TETRA-HD Investigators.3 1University of Rochester School of Medicine and Dentistry, Rochester, NY; 2 Boston University School of Medicine, Boston, MA, USA;3Includes all authors listed in appendix to Neurology 2006;66:366-372.

2:30-2:45 PM
Onset Symptoms in Huntington’s Disease: Association with Gender of Affected Parent
M.B. Harrison, C.A. Manning, L.J. Currie. University of Virginia, Charlottesville, VA, USA.

2:45-3:00 PM
Brain Metabolism in Presymptomatic Huntington’s Disease: A Longitudinal FDG PET Study
A. Feigin,1 C. Tang,1 Y. Ma,1 M. Guttman,2 J.S. Paulsen,3 D. Eidelberg.1 1Feinstein Institute for Medical Research, North Shore – LIJ Health System, Manhasset, NY; 2Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; 3Departments of Psychiatry and Neurology, University of Iowa College of Medicine, Iowa City, IA, USA.

3:00-3:15 PM
BREAK

3:15-3:30 PM
Chronic Pain in Machado-Joseph Disease
M.C. França Jr,1 A. D’Abreu,1 A. Nucci,1 I. Lopes-Cendes,2 J. H. Friedman.3 1Department of Neurology, Universidade Estadual de Campinas – UNICAMP, Campinas, Brazil; 2Department of Medical Genetics, Universidade Estadual de Campinas – UNICAMP, Campinas, Brazil; 3 Department of Clinical Neurosciences, Brown University Medical School, RI, USA.

3:30-3:45 PM
Medication Effects on Psychosis and Motor Function in Dementia with Lewy Bodies (DLB)
J.G. Goldman,1 C.G. Goetz,1 M. Brandabur,2 M. Sanfilippo,2 S.E. Leurgans,1 W. Fan.1 1Rush University Medical Center, Chicago, IL; 2Alexian Brothers Neuroscience Institute, Hoffman Estates, IL, USA.

3:45-4:00 PM
Quantitative Tremor Analysis in Welders: Comparison with Idiopathic Parkinson’s Disease (IPD) and Essential Tremor (ET)
J. Sanchez-Ramos,1 D. Reimer,2 T. A. Zesiewicz,1 K. Sullivan,1 P. A. Nausieda.2 1University of South Florida College of Medicine, Tampa FL; 2Parkinson Research Institute at Aurora Sinai Medical Center, Milwaukee, WI, USA.

4:00-4:15 PM
Embouchure Dystonia (ED) and Focal Task-specific Dystonia of the Hand (FTSDh) in Musicians: Susceptibility Factors or Peripheral Modifiers?
S.J. Frucht. Columbia University Medical Center, New York, NY, USA.

4:15-4:30 PM
Abnormal Affective Startle Modulation in Psychogenic Movement Disorders
P. Seignourel,1 M. S. Okun,2 K. Miller,1 I. Kellison,1 R. Bauer,1 H. H. Fernandez,2 R.L. Rodriguez,2 M. Repetto,3 D. Bowers.1 1Department of Clinical and Health Psychology, University of Florida Movement Disorders Center, McKnight Brain Institute, Gainesville, FL; 2Department of Neurology, University of Florida Movement Disorders Center, McKnight Brain Institute, Gainesville, FL; 3Department of Psychiatry, University of Florida Movement Disorders Center, McKnight Brain Institute, Gainesville, FL, USA.

~ POSTER SESSION ~

Posters will be staffed from Noon to 1:30 PM
in the Grand Ballroom E & F.

Poster 1 (PD)
Racial and Socioeconomic Disparities in Elderly Patients with Parkinsonism
L.M. Shulman,1 M. Baumgarten,2 A.L. Gruber-Baldini,2 K.E. Anderson,3 M. Shardell,2 P.S. Fishman,1 S.G. Reich,1 and W.J. Weiner.1 1University of Maryland School of Medicine, Dept of Neurology, Baltimore, MD; 2University of Maryland School of Medicine, Dept of Epidemiology and Preventive Medicine, Baltimore, MD; 3University of Maryland School of Medicine, Dept of Psychiatry, Baltimore, MD, USA.

Poster 2 (PD)
Cognitive and Affective Symptoms of Hispanic Patients Diagnosed with Idiopathic Parkinson’s Disease: A Case Series
L. San Miguel-Montes, I. Pita, C. Serrano, M. Margarida, O. Cardona. Neurology Section University of Puerto Rico School of Medicine, Medical Sciences Campus, San Juan, Puerto Rico.

Poster 3 (PD)
8,12-iso-IPF2?-VI Isoprostanes as a Possible Biomarker for Dementia in Parkinson’s Disease
A. Siderowf, J. Connolly, D. Mu and D. Pratico. University of Pennsylvania, Philadelphia, PA, USA.

Poster 4 (PD)
Associated Risk Factors for Compulsive Behaviors in Parkinson’s Disease
J.S. Hui,1 G. Murdock,1 J. Moon,2 D. Fly,2 M. Gomez,1 M. Langille,1 S. Christensen,1 M.D. Welsh.1 1University of Southern California, Los Angeles, CA; 2Fuller Theological Seminary School of Psychology, Pasadena, CA, USA.

Poster 5 (PD)
Is Pathological Gambling Associated with Pramipexole Therapy in Parkinson Disease?
A. Imamura, J. Slowinski, L. Brown, R.J. Uitti, Z.K. Wszolek, Y.E. Geda. Department of Neurology, Mayo Clinic Jacksonville, Jacksonville, FL, USA.

Poster 6 (PD)
Safety and Tolerability of Transdermal Rotigotine in Early-Stage Parkinson’s Disease
M. Tagliati,1 R.L. Watts,2 J. Patton,3 W. Poewe,4 B. Boroojerdi.5 1Mount Sinai School of Medicine, New York, NY; 2University of Alabama at Birmingham, Birmingham, AL; 3Asheville Neurology Specialists, P.A., Asheville, NC; 4Medical University Innsbruck, Innsbruck, Austria; 5SCHWARZ PHARMA AG, Monheim,Germany.

Poster 7 (PD)
Long-term Safety and Efficacy of the Rotigotine Transdermal Patch in Early-Stage Parkinson’s Disease
R.L. Watts,1 R.Pahwa,2 K.E. Lyons,2 B.Boroojerdi.3 1University of Alabama at Birmingham, Birmingham, AL, USA; 2University of Kansas Medical Center, Kansas City, MO, USA; 3SCHWARZ PHARMA AG, Monheim, Germany.

Poster 8 (PD)
Ropinirole 24-Hour Prolonged Release Reduces “Off” Time and Improves Mood when Used as Adjunctive Therapy in Patients with Parkinson’s Disease Not Optimally Controlled with L-Dopa
R.A. Hauser,1 M.A. Stacy,2 B.P. Hersh.3 1University of South Florida, Tampa, FL; 2Duke University Medical Center, Durham, NC; 3Harvard Vanguard Medical Associates and Harvard Medical School, Boston, MA, USA.

Poster 9 (PD)
Low-frequency Repetitive Transcranial Magnetic Stimulation for Treatment of Levodopa-Induced Dyskinesias: An Open-Labeled Study with Blinded Assessments
A. Wagle-Shukla, M. Angel, C. Zadikoff, M. Enjati, C. Gunraj, A.E. Lang, R. Chen. Division of Neurology, Krembil Neuroscience Centre, Toronto Western Research Institute, University Health Network, University of Toronto, Toronto, Ontario, Canada.

Poster 10 (PD)
Deep Brain Stimulation Decreases the Risk for Parkinsonism-Hyperpyrexia Syndrome and Suppresses Levodopa-Induced Dyskinesias: A Case Report
O.S. Klepitskaya, W.L. Cole, J.M. Henderson, H.M. Bronte-Stewart. Stanford University, Stanford, CA, USA.

Poster 11 (PD)
Unilateral vs. Bilateral Subthalamic Nucleus Deep Brain Stimulation in Parkinson Disease
A. Samii,1 V.E. Kelly,2 J.C. Slimp,2 A. Shumway-Cook,2 R. Goodkin.3 1Department of Neurology, University of Washington, Seattle Parkinson Disease Research Education and Clinical Center (PADRECC), VA Puget Sound Health Care System, Seattle, WA; 2Department of Rehabilitation Medicine, University of Washington, Seattle, WA; 3Department of Neurological Surgery, University of Washington, Seattle, WA, USA.

Poster 12 (PD)
The Florida Surgical Questionnaire for Parkinson’s Disease (FLASQ-PD): A Potential Triage Tool for Cognitive Dysfunction in DBS Candidates
I. Halkias,1 M. Krishnan, 2 P. Seignourel,2 D. Bowers, C.A. Rosado,1 H.H. Fernandez,1 R.L. Rodriguez,1 F. Skidmore,1 K.D. Foote,3 M.S. Okun.1,3 1 Department Department of Neurology, University of Florida Movement Disorders Center, McKnight Brain Institute, Gainesville, FL; 2 Department of Clinical and Health Psychology, University of Florida Movement Disorders Center, McKnight Brain Institute, Gainesville, FL; 3 Department of Neurosurgery, University of Florida Movement Disorders Center, McKnight Brain Institute, Gainesville, FL, USA.

Poster 13 (PD)
Milestones of Disease Progression and Disability in Parkinson's Disease
S.A. Parashos, C.L. Wielinski. Struthers Parkinson’s Center, Golden Valley, MN, USA.

Poster 14 (PD)
Nonsteroidal Anti-Inflammatory Drug Use and the Risk of Parkinson’s Disease
M. Etminan,1B.C. Carleton,2A. Samii.3 1Center for Clinical Epidemiology and Evaluation, Vancouver Hospital and University of British Columbia Vancouver, BC, Canada; 2Faculty of Pharmaceutical Sciences, University of British Columbia Vancouver, BC, Canada; 3University of Washington School of Medicine, Seattle VA Parkinson Disease Research Education and Clinical center (PADRECC), Seattle, WA, USA.

Poster 15 (PD)
Drug-Induced Parkinsonism: Still Common, Under-Recognized, and Treatable
C.D. Esper, S.A. Factor. Emory University, Atlanta, Georgia, USA.

Poster 16 (OMD)
A Rater-Blinded, Exploratory, Tolerability and Efficacy Study of Sodium Oxybate (Xyrem) in Patients with Treatment-Refractory Hyperkinetic Movement Disorders
S.J. Frucht,1 Y. Bordelon,2 P.E. Greene,1 A. Floyd,1 S. Pullman,1 E.D. Louis.1 1Columbia University Medical Center, New York, NY; 2UCLA Medical Center, Los Angeles, CA, USA.

Poster 17 (OMD)
Tolerability and Efficacy of Ropinirole in Patients with Intermittent Restless Legs Syndrome (RLS): Open-Label Results
J. Black,1 K. Merchant.2 1Stanford University, Stanford, CA; 2GlaxoSmithKline, Research Triangle Park, NC, USA.

Poster 18 (OMD)
Open-Label Flexible Dosing 8-Week Trial of Aripiprazole in Tourette Syndrome
D. Duane, G. Heimburger, S. Flecky, J. Flutie, R. Owen, K. Zebatto. Arizona Dystonia Institute, Scottsdale, AZ, USA.

Poster 19 (OMD)
Postural Anomalies in Tourette Syndrome
M. Lemay, S. Chouinard, P. Lesperance, G. Rouleau, F. Richer. University of Montreal Hospital Center, Montreal, QC, Canada.

Poster 20 (OMD)
Safety and Tolerability of Tetrabenazine Use with Concomitant Medications in Huntington’s Chorea
M. S. Jog, N. Khandekar, A. Attar. University of Western Ontario, London Ontario, Canada.

Poster 21 (OMD)
Willingness to Consent for Future Use of DNA Collected in the Prospective Huntington At Risk Observational Study (PHAROS)
Huntington Study Group PHAROS Investigators (M. Aileen Shinaman, presenter), University of Rochester, Rochester, NY, USA.

Poster 22 (OMD)
Essential Tremor Phenotyping and Molecular Genetics: ET Database Cases and a New Large Pedigree
AR Rosen, AI Levey, M Bouzyk, T Wichmann, SA Factor, CM Testa. Emory University, Atlanta, GA, USA.

Poster 23 (OMD)
Lower Limb Holmes Tremor with Hypertrophic Olivary Degeneration
M. Walker,1 H.M. Kim,2 and A. Samii.3 1Department of Neurology, University of Washington, Seattle, WA; 2Department of Neurology, University of Washington and the VA Puget Sound Health Care System, Seattle, WA; 3Department of Neurology, University of Washington and the Seattle Parkinson Disease Research Education and Clinical Center (PADRECC) at the VA Puget Sound Health Care System, Seattle, WA, USA.

Poster 24 (OMD)
Mozart’s Movements
J. Sanchez-Ramos. University of South Florida College of Medicine, Tampa, FL, USA.

Poster 25 (OMD)
Paraneoplastic Neurologic Autoimmunity with DLB-like Presentation
W.T. Hu, D.A. Drubach, K.A. Josephs, J.E. Parisi, V.A. Lennon, B.F. Boeve. Department of Neurology, Mayo Clinic, Rochester, MN, USA.

Poster 26 (OMD)
Pain in Cervical Dystonia is Associated with Female Gender and Greater Disability
C.L. Comella, W. Fann, S. Leurgans and The Dystonia Study Group. Rush University Medical Center, Department of Neurological Sciences, Chicago, IL, USA.

Poster 27 (OMD)
Validation of a Computerized Neuropsychological Assessment (Mindstreams) in Movement Disorders: Interim Analysis
G.M. Doniger,1 M.S. Okun,2 E.S. Simon,1 R.L. Rodriguez,2 C.E. Jacobson,2 D. Weiss,2 C. Rosado,2 and H.H. Fernandez.2 1Department of Clinical Sciences, Neurotrax Corporation, New York, NY; 2Department of Neurology, University of Florida, Gainesville, FL, USA.

Poster 28 (PD) Late-Breaking Research
Unmasking Differences Between Normal and Pathological Neural Circuits: Functional Brain Mapping in a Rat Model of Nigrostriatal Damage During Locomotor Challenge
J. Yang, T.S. Sadler, J-M.I. Maarek, T.K. Givrad, G.M. Petzinger, D.P. Holschneider. University of Southern California, Los Angeles, CA, USA.

Poster 29 (PD) Late-Breaking Research
Clinical and Economic Determinants of Caregiver Burden in Parkinson’s Disease
D. J. Houghton,1 P. J. Barbour,2 N. A. Leopold,3 J. H. Lee,1 A. D. Siderowf.1 1Department of Neurology, University of Pennsylvania, Philadelphia, PA; 2Department of Clinical Medicine (Neurology), Lehigh Valley Hospital and Health Network, Allentown, PA; 3Department of Medicine (Neurology), Crozer-Chester Medical Center, Upland, PA, USA.

Poster 30 (OMD) Late-Breaking Research
Longitudinal Investigation of At-Risk Members of the PPND Family: 8 Year Follow-up
C.A. McRae,1 E. Chaves,1 K.Day,1 T. Ferman,2 G. Hartsock,1 E. Sullivan,1 Z.K. Wszolek.2 1University of Denver, Denver, CO; 2Mayo Clinic, Jacksonville, FL, USA.

PSG OVERVIEW | PARKINSON'S DISEASE OVERVIEW | WHAT IS A CLINICAL TRIAL

CLINICAL TRIALS IN PROGRESS

COMPLETED CLINICAL TRIALS | PSG / MDS SYMPOSIA | PUBLICATIONS / ABSTRACTS

CONTRIBUTIONS | OTHER USEFUL LINKS